NASDAQ: VRCAVerrica Pharmaceuticals Inc Stock Ownership - Who owns Verrica Pharmaceuticals?
Insider buying vs selling
Have Verrica Pharmaceuticals Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Paul B. Manning | Director | 2025-11-25 | 2,750,762 | $4.24 | $11.67MBuy |
| John J. Kirby | Interim CFO | 2025-11-25 | 3,536 | $4.24 | $15.00kBuy |
| Paul B. Manning | Director | 2025-11-25 | 1,375,380 | $4.24 | $5.83MBuy |
| David Zawitz | Chief Operating Officer | 2025-11-25 | 10,000 | $4.24 | $42.42kBuy |
| Jayson Rieger | CEO and President | 2025-11-25 | 94,311 | $4.24 | $400.07kBuy |
| Noah L. Rosenberg | CMO | 2025-11-25 | 2,357 | $4.24 | $10.00kBuy |
| Christopher G. Hayes | CHIEF LEGAL OFFICER | 2025-03-17 | 4,315 | $0.65 | $2.80kSell |
VRCA insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when VRCA insiders and whales buy or sell their stock.
VRCA Shareholders
What type of owners hold Verrica Pharmaceuticals Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Paul B. Manning | 108.71% | 10,316,285 | $57.46M | Insider |
| Perceptive Advisors LLC | 74.81% | 7,099,182 | $39.54M | Insider |
| Bkb Growth Investments LLC | 35.28% | 3,348,372 | $18.65M | Insider |
| Matt Davidson | 26.94% | 2,556,179 | $14.24M | Insider |
| John A. Stalfort Iii | 19.74% | 1,873,800 | $10.44M | Insider |
| Armistice Capital LLC | 11.79% | 1,118,925 | $6.23M | Institution |
| Caligan Partners LP | 9.74% | 923,910 | $5.15M | Institution |
| Caligan Partners LP | 9.74% | 923,910 | $5.15M | Insider |
| Affinity Asset Advisors LLC | 7.45% | 707,338 | $3.94M | Institution |
| Velan Capital Investment Management LP | 4.97% | 471,559 | $2.63M | Institution |
VRCA vs Biotech Stocks
Verrica Pharmaceuticals Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.